Drugs / QLS4131
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07001839 | Jun 2025 → Dec 2026 expected | systemic lupus erythematosus | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06500507 | Aug 2024 → Mar 2026 overdue | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07560449 | Jun 2026 → Jun 2028 expected | plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS4131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07560449 ↗ |
| Modality | Monoclonal antibody | “QLS4131 is a novel tri-specific humanized antibody.” NCT06500507 ↗ |
| Route | Subcutaneous | “QLS4131 will be administered subcutaneously.” NCT07560449 ↗ |